Scientists are revealing mroe about why TDP-43 has long been linked to the neurodegenerative disorders Alzheimer's, FTD, and ...

Tempus AI TEM reported non-GAAP profit in the third quarter of 2025 as genomics testing and data services gained momentum.

The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest ...

Arima Genomics, Inc ., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced new data to be presented at the ...

Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual, ...

BOSTON - Complete Genomics and SOPHiA GENETICS (NASDAQ:SOPH) announced Tuesday a collaboration to launch cancer genomic testing solutions that combine SOPHiA’s AI-powered analytics with Complete ...

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven ...

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (SOPH) (NASDAQ: SOPH), a global leader in ...